Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.
FDA designation opens accelerated pathway for future AdenoVerse cancer programs
The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.
Regulator confirms platform is reproducible across multiple disease targets
To qualify, the FDA required evidence that the platform is well characterized, reproducible, and adaptable across multiple products without compromising quality, manufacturing or safety. The agency determined AdenoVerse meets this bar and is likely to generate efficiencies in development, manufacturing and regulatory review.
PRGN-2009 positioned as near-term beneficiary across HPV-linked cancers
Precigen President and CEO Helen Sabzevari said the near-term impact will be most significant for PRGN-2009, currently in Phase 2 studies combined with pembrolizumab for cervical cancer (NCT06157151) and HPV-associated oropharyngeal squamous cell carcinoma (NCT05996523). Sabzevari said the designation's potential extends beyond PRGN-2009 to future candidates targeting additional cancers and other diseases, including HPV-positive head and neck, anal, vulvar and vaginal malignancies.
Company advances redosing study while broadening platform's addressable indications
An open-label study evaluating redosing of PAPZIMEOS in adults with RRP is currently enrolling (NCT06538480). The platform designation applies broadly to AdenoVerse-based product candidates addressing HPV-positive malignancies and other diseases beyond the currently approved indication.